TY - JOUR
T1 - Interictal, circulating sphingolipids in women with episodic migraine
AU - Peterlin, B. Lee
AU - Mielke, Michelle M.
AU - Dickens, Alex M.
AU - Chatterjee, Subroto
AU - Dash, Paul
AU - Alexander, Guillermo
AU - Vieira, Rebeca V.A.
AU - Bandaru, Veera Venkata Ratnam
AU - Dorskind, Joelle M.
AU - Tietjen, Gretchen E.
AU - Haughey, Norman H.
N1 - Publisher Copyright:
© 2015 American Academy of Neurology.
PY - 2015/10/6
Y1 - 2015/10/6
N2 - Objective: To evaluate interictal, circulating sphingolipids in women migraineurs. Methods: In the fasting state, serum samples were obtained pain-free from 88 women with episodic migraine (EM; n 52) and from controls (n 36). Sphingolipids were detected and quantified by high-performance liquid chromatography coupled with tandem mass spectrometry using multiple reaction monitoring. Multivariate logistic regression was used to examine the association between serum sphingolipids and EM odds. A recursive partitioning decision tree based on the serum concentrations of 10 sphingolipids was used to determine the presence or absence of EM in a subset of participants. Results: Total ceramide (EM 6,502.9 ng/mL vs controls 10,518.5 ng/mL; p < 0.0001) and dihydroceramide (EM 39.3 ng/mL vs controls 63.1 ng/mL; p < 0.0001) levels were decreased in those with EM as compared with controls. Using multivariate logistic regression, each SD increase in total ceramide (odds ratio [OR] 0.07; 95% confidence interval [CI]: 0.02, 0.22; p < 0.001) and total dihydroceramide (OR 0.05; 95% CI: 0.01, 0.21; p < 0.001) levels was associated with more than 92% reduced odds of migraine. Although crude sphingomyelin levels were not different in EM compared with controls, after adjustments, every SD increase in the sphingomyelin species C18:0 (OR 4.28; 95% CI: 1.87, 9.81; p 0.001) and C18:1 (OR 2.93; 95% CI: 1.55, 5.54; p 0.001) was associated with an increased odds of migraine. Recursive portioning models correctly classified 14 of 14 randomly selected participants as EM or control. Conclusion: These results suggest that sphingolipid metabolism is altered in women with EM and that serum sphingolipid panels may have potential to differentiate EM presence or absence. Classification of evidence: This study provides Class III evidence that serum sphingolipid panels accurately distinguish women with migraine from women without migraine.
AB - Objective: To evaluate interictal, circulating sphingolipids in women migraineurs. Methods: In the fasting state, serum samples were obtained pain-free from 88 women with episodic migraine (EM; n 52) and from controls (n 36). Sphingolipids were detected and quantified by high-performance liquid chromatography coupled with tandem mass spectrometry using multiple reaction monitoring. Multivariate logistic regression was used to examine the association between serum sphingolipids and EM odds. A recursive partitioning decision tree based on the serum concentrations of 10 sphingolipids was used to determine the presence or absence of EM in a subset of participants. Results: Total ceramide (EM 6,502.9 ng/mL vs controls 10,518.5 ng/mL; p < 0.0001) and dihydroceramide (EM 39.3 ng/mL vs controls 63.1 ng/mL; p < 0.0001) levels were decreased in those with EM as compared with controls. Using multivariate logistic regression, each SD increase in total ceramide (odds ratio [OR] 0.07; 95% confidence interval [CI]: 0.02, 0.22; p < 0.001) and total dihydroceramide (OR 0.05; 95% CI: 0.01, 0.21; p < 0.001) levels was associated with more than 92% reduced odds of migraine. Although crude sphingomyelin levels were not different in EM compared with controls, after adjustments, every SD increase in the sphingomyelin species C18:0 (OR 4.28; 95% CI: 1.87, 9.81; p 0.001) and C18:1 (OR 2.93; 95% CI: 1.55, 5.54; p 0.001) was associated with an increased odds of migraine. Recursive portioning models correctly classified 14 of 14 randomly selected participants as EM or control. Conclusion: These results suggest that sphingolipid metabolism is altered in women with EM and that serum sphingolipid panels may have potential to differentiate EM presence or absence. Classification of evidence: This study provides Class III evidence that serum sphingolipid panels accurately distinguish women with migraine from women without migraine.
UR - http://www.scopus.com/inward/record.url?scp=84943229492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943229492&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000002004
DO - 10.1212/WNL.0000000000002004
M3 - Article
C2 - 26354990
AN - SCOPUS:84943229492
SN - 0028-3878
VL - 85
SP - 1214
EP - 1223
JO - Neurology
JF - Neurology
IS - 14
ER -